Atlas Trials

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Clinical trial NCT02157883 · COMPLETED

Trial details

NCT number
NCT02157883
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
Start date
2014-11-06
Primary completion
2015-04-03
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.